Cardiovascular health in pediatric heart transplant patients.


Journal

BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539

Informations de publication

Date de publication:
01 04 2022
Historique:
received: 17 02 2021
accepted: 21 03 2022
entrez: 2 4 2022
pubmed: 3 4 2022
medline: 6 4 2022
Statut: epublish

Résumé

Ideal "cardiovascular health" (CVH)-optimal diet, exercise, nonsmoking, BMI, BP, lipids, and glucose-is associated with healthy longevity in adults. Pediatric heart transplant (HT) patients may be at risk for suboptimal CVH. Single-center retrospective study of HT patients 2003-2014 who survived 1 year post-transplant. Five CVH metrics were collected at listing, 1, 3 and 5 years post-transplant (diet and exercise were unavailable). CVH was scored by summing individual metrics: ideal = 2, intermediate = 1, and poor = 0 points; total scores of 8-10 points were considered high (favorable). CVH was compared between HT patients and the US pediatric population (GP) utilizing NHANES 2007-2016. Logistic regression was performed to examine the association of CVH 1 year post-transplant with a composite adverse outcome (death, re-listing, coronary vasculopathy, or chronic kidney disease) 3 years post-transplant. We included 110 HT patients (median age at HT: 6 years [range 0.1-21]) and 19,081 NHANES participants. CVH scores among HT patients were generally high at listing (75%), 1 (74%), 3 (87%) and 5 (76%) years post-transplant and similar to GP, but some metrics (e.g., glucose) were worse among HT patients. Among HT patients, CVH was poorer with older age and non-Caucasian race/ethnicity. Per 1-point higher CVH score, the demographic-adjusted OR for adverse outcomes was 0.95 (95% CI, 0.7-1.4). HT patients had generally favorable CVH, but some metrics were unfavorable and CVH varied by age and race/ethnicity. No significant association was detected between CVH and adverse outcomes in this small sample, but study in a larger sample is warranted.

Sections du résumé

BACKGROUND
Ideal "cardiovascular health" (CVH)-optimal diet, exercise, nonsmoking, BMI, BP, lipids, and glucose-is associated with healthy longevity in adults. Pediatric heart transplant (HT) patients may be at risk for suboptimal CVH.
METHODS
Single-center retrospective study of HT patients 2003-2014 who survived 1 year post-transplant. Five CVH metrics were collected at listing, 1, 3 and 5 years post-transplant (diet and exercise were unavailable). CVH was scored by summing individual metrics: ideal = 2, intermediate = 1, and poor = 0 points; total scores of 8-10 points were considered high (favorable). CVH was compared between HT patients and the US pediatric population (GP) utilizing NHANES 2007-2016. Logistic regression was performed to examine the association of CVH 1 year post-transplant with a composite adverse outcome (death, re-listing, coronary vasculopathy, or chronic kidney disease) 3 years post-transplant.
RESULTS
We included 110 HT patients (median age at HT: 6 years [range 0.1-21]) and 19,081 NHANES participants. CVH scores among HT patients were generally high at listing (75%), 1 (74%), 3 (87%) and 5 (76%) years post-transplant and similar to GP, but some metrics (e.g., glucose) were worse among HT patients. Among HT patients, CVH was poorer with older age and non-Caucasian race/ethnicity. Per 1-point higher CVH score, the demographic-adjusted OR for adverse outcomes was 0.95 (95% CI, 0.7-1.4).
CONCLUSIONS
HT patients had generally favorable CVH, but some metrics were unfavorable and CVH varied by age and race/ethnicity. No significant association was detected between CVH and adverse outcomes in this small sample, but study in a larger sample is warranted.

Identifiants

pubmed: 35365073
doi: 10.1186/s12872-022-02575-z
pii: 10.1186/s12872-022-02575-z
pmc: PMC8973961
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

139

Informations de copyright

© 2022. The Author(s).

Références

J Am Coll Cardiol. 2015 Aug 4;66(5):547-57
pubmed: 26227194
Congenit Heart Dis. 2012 Jul-Aug;7(4):324-35
pubmed: 22613206
J Heart Lung Transplant. 2006 Oct;25(10):1192-8
pubmed: 17045931
Pediatr Transplant. 2007 Aug;11(5):459-60
pubmed: 17631010
J Heart Lung Transplant. 2018 Oct;37(10):1184-1195
pubmed: 30293614
J Am Coll Cardiol. 2001 Jul;38(1):206-13
pubmed: 11451276
J Am Heart Assoc. 2018 May 17;7(11):
pubmed: 29773573
JAMA Netw Open. 2019 May 3;2(5):e194758
pubmed: 31150075
Circulation. 2010 Apr 20;121(15):1768-77
pubmed: 20404268
Circulation. 2001 May 1;103(17):2144-52
pubmed: 11331254
Pediatr Transplant. 2011 Nov;15(7):699-705
pubmed: 22004544
PLoS One. 2015 Jul 08;10(7):e0131537
pubmed: 26154254
J Heart Lung Transplant. 2019 Jan;38(1):102-103
pubmed: 30563620
Pediatr Transplant. 2000 Aug;4(3):193-9
pubmed: 10933319
Pediatr Transplant. 2018 Mar;22(2):
pubmed: 29377429
J Heart Lung Transplant. 2005 Jun;24(6):645-51
pubmed: 15949722
Circulation. 2017 May 2;135(18):1693-1701
pubmed: 28461414
J Heart Lung Transplant. 2006 Oct;25(10):1199-205
pubmed: 17045932
Circulation. 2014 Nov 4;130(19):1676-83
pubmed: 25274000
Pediatr Transplant. 2019 Feb;23(1):e13316
pubmed: 30393915
Pediatr Transplant. 2016 Nov;20(7):963-969
pubmed: 27421915
Circulation. 2012 May 29;125(21):2595-602
pubmed: 22547667
Prev Med. 2019 Feb;119:87-98
pubmed: 30594534
J Biomed Inform. 2016 Apr;60:95-103
pubmed: 26828957
J Heart Lung Transplant. 2012 Sep;31(9):1003-8
pubmed: 22789135
Pediatr Transplant. 2005 Aug;9(4):523-30
pubmed: 16048607
J Heart Lung Transplant. 2009 Dec;28(12):1273-8
pubmed: 19783177
Am J Transplant. 2003 Aug;3(8):994-8
pubmed: 12859535
Am J Kidney Dis. 2016 Aug;68(2):212-218
pubmed: 26970941
N Engl J Med. 2003 Sep 4;349(10):931-40
pubmed: 12954741
Circulation. 2010 Feb 2;121(4):586-613
pubmed: 20089546
J Heart Lung Transplant. 2004 Mar;23(3):317-22
pubmed: 15019641
Ann Thorac Surg. 2014 Dec;98(6):2145-50; discussion 2150-1
pubmed: 25443019
J Heart Lung Transplant. 2001 Feb;20(2):230
pubmed: 11250439
Transplant Proc. 2011 Jul-Aug;43(6):2257-9
pubmed: 21839250
JAMA. 2016 Jun 7;315(21):2292-9
pubmed: 27272581

Auteurs

Carmel Bogle (C)

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA. carmel.bogle@gmail.com.
University of Maryland Children's Heart Program, Baltimore, MD, USA. carmel.bogle@gmail.com.

Amanda Marma Perak (A)

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Sarah J Wilkens (SJ)

University of Louisville School of Medicine, Louisville, KY, USA.

Alaa Aljiffry (A)

Children's Healthcare of Atlanta, Atlanta, GA, USA.

Karen Rychlik (K)

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

John M Costello (JM)

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
Medical University of South Carolina Children's Health, Charleston, SC, USA.

Donald M Lloyd-Jones (DM)

Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Elfriede Pahl (E)

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH